ReviewFrontiers in endocrinology2019
Toward a Diagnostic Score in Cushing's Syndrome.
Review in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 74 citations in OpenAlex.
- Hypercortisolism: An Under-Recognised Pathway Linked to Multi-System Complications.Diabetes, obesity & metabolism · 2026Review
- How Common Is Hypercortisolism in Patients With Hypertension? Risk Factors, Epidemiology, and Making a Diagnosis.Diabetes, obesity & metabolism · 2026Review
- Hypercortisolism: Causes, Consequences and Clinical Significance - A Review of Pathophysiology.Diabetes, obesity & metabolism · 2026Review
- Biases of large language models in diagnosing Cushing's syndrome.World journal of methodology · 2026Review
- Response to comment on Buse et al. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care 2025;48:2012-2020.Diabetes care · 2026Article
- Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design.JACC. Advances · 2026Article
- Clinical characteristics, diagnosis, and treatment of Cushing's syndrome: analysis of a multicenter registry in Antioquia, Colombia.Therapeutic advances in endocrinology and metabolism · 2026Article
- Development and validation of clinical screening systems for Cushing disease in the United States.Pituitary · 2025Article
- Identification of Endogenous Hypercortisolism and the Effect of Mifepristone Treatment in Patients With Difficult-to-Manage Diabetes: A Case Series.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Screening for endogenous hypercortisolism in patients with osteoporosis and fractures: why, when and how.Journal of endocrinological investigation · 2025Review
- Who and how to screen for endogenous hypercortisolism in type 2 diabetes mellitus or obesity.Journal of endocrinological investigation · 2025Review
- Current Challenges and Future Directions in the Assessment of Glucocorticoid Status.Endocrine reviews · 2024Review
- Diagnostic dilemma in Cushing's syndrome: discrepancy between patient-reported and physician-assessed manifestations.Endocrine · 2024Article
- "The healthcare system did fail me repeatedly": a qualitative study on experiences of healthcare among Canadian women with Cushing's syndrome.BMC primary care · 2024Article
- The glucocorticoid receptor acts locally to protect dystrophic muscle and heart during disease.Disease models & mechanisms · 2024Article
- The relationship between temporal muscle thickness and disease activity in Cushing's disease.Journal of endocrinological investigation · 2023Article
- PPARG dysregulation as a potential molecular target in adrenal Cushing's syndrome.Frontiers in endocrinology · 2023Article
- Emerging diagnostic methods and imaging modalities in cushing's syndrome.Frontiers in endocrinology · 2023Review
- Editorial: A year in review: discussions in adrenal endocrinology.Frontiers in endocrinology · 2023Article
- Proximal muscle weakness as the sole manifestation of Cushing's disease, misdiagnosed as dermatomyositis: a case report.Journal of medical case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cushing's syndrome (CS) is a classical rare disease: it is often suspected in patients who do not have the disease; at the same time, it takes a mean of 3 years to diagnose CS in affected individuals. The main reason is the extreme rarity (1-3/million/year) in combination with the lack of a single lead symptom. CS has to be suspected when a combination of signs and symptoms is present, which together make up the characteristic phenotype of cortisol excess. Unusual fat distribution affecting the face, neck, and trunk; skin changes including plethora, acne, hirsutism, livid striae, and easy bruising; and signs of protein catabolism such as thinned and vulnerable skin, osteoporotic fractures, and proximal myopathy indicate the need for biochemical screening for CS. In contrast, common symptoms like hypertension, weight gain, or diabetes also occur quite frequently in the general population and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.